(Adds analyst comment, details on Opdivo cancer drug, shares). By Ransdell Pierson. Oct 24 (Reuters) - Bristol-Myers Squibb Co reported better-than-expected third-quarter results, as sizzling sales of its treatments for blood clots, cancer and arthritis helped ...
Bristol-Myers tops Street 3Q forecasts
Bristol-Myers Tops Estimates on Strong Drug Sales
Related articles »